Hiperplasia nodular regenerativa hepática múltiple asociada a oxaliplatino

Ramia, Jose Manuel; Plaza, Roberto de la; Perna, Cristian; Adel, Farah; Kuhnhardt, Andree.
Cir. Esp. (Ed. impr.) ; 94(1): 52-54, ene. 2016. ilus
Artículo en Español | IBECS (España) | ID: ibc-148430

Documentos relacionados

  1. Genetic polymorphisms in the mismatch repair pathway (MMR) genes contribute to hematological and gastrointestinal toxicity in North Indian lung cancer patients treated with platinum-based chemotherapy.
  2. Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo.
  3. A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer.
  4. Which patients with early-stage triple-negative breast cancer should receive a platinum?
  5. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
  6. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
  7. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.
  8. Estimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy.
  9. Platinum-induced neurotoxicity and preventive strategies: past, present, and future.
  10. Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data.